Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma

Journal of Clinical Oncology

Volumn 23, Issue 4, 2005, Pages 694-704

  Czuczman, Myron S ^a   Koryzna, A ^a   Mohr, A ^a   Stewart, C ^a   Donohue, K ^a   Blumenson, L ^a   Bernstein, Z P ^a   McCarthy, P ^a   Alam, A ^a   Hernandez Ilizaliturri, F ^a   Skipper, M ^a   Brown, K ^a   Chanan Khan, A ^a   Klippenstein, D ^a   Loud, P ^a   Rock, M K ^a   Benyunes, M ^a   Grillo Lopez, A ^a   Bernstein, S H ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; ANTIEMETIC AGENT; CORTICOSTEROID DERIVATIVE; FLUDARABINE; GALLIUM; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PROTEIN BCL 2; RITUXIMAB; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; VIDARABINE;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; FOLLOW UP; HERPES SIMPLEX; HERPES ZOSTER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERSTITIAL PNEUMONIA; LIVER FUNCTION TEST; MALE; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIDE EFFECT; T CELL DEPLETION; THROMBOCYTOPENIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VOMITING; IMMUNOLOGY; MIDDLE AGED; MORTALITY; PROTO ONCOGENE; T LYMPHOCYTE SUBPOPULATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FLOW CYTOMETRY; GENES, BCL-2; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, LOW-GRADE; MALE; MIDDLE AGED; T-LYMPHOCYTE SUBSETS; VIDARABINE;

EID: 20044368632     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.172     Document Type: Article

References (45)

1. Armitage JO: Treatment of non-Hodgkin's lymphoma. N Engl J Med 328:1023-1030, 1993
2. Gallagher CJ, Gregory WM, Jones AE, et al: Follicular lymphoma: Prognostic factors for response and survival. J Clin Oncol 4:1470-1480, 1986
3. Adkins JC, Peters DH, Markham A: Fludarabine: An update of its pharmacology and use in the treatment of haematological malignancies. Drugs 53:1005-1037, 1997
4. Bellosillo B, Villamor N, Colomer D, et al: In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood 94: 2836-2843, 1999
5. Flinn IW, Byrd JC, Morrison C, et al: Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood 96:71-75, 2000
6. Hochster H, Weller E, Kuzel T, et al: Increased mortality associated with higher dose cyclophosphamide plus fludarabine in advanced stage indolent lymphoma patients treated on E1496, an ECOG and CALGB study. Proc Am Soc Clin Oncol 21:282a, 2002 (abstr 1125)
7. McLaughlin P, Hagemeister FB, Romaguera JE, et al: Fludarabine, mitoxantrone, and dexamethasone: An effective new regimen for indolent lymphoma. J Clin Oncol 14:1262-1268, 1996
8. McLaughlin P, Hagemeister FB, Swan F Jr, et al: Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol 12:575-579, 1994
9. Tsimberidou AM, McLaughlin P, Younes A, et al: Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. Blood 100:4351-4357, 2002
10. Maloney DG, Grillo-Lopez AJ, White CA, et al: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90: 2188-2195, 1997
11. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al: IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 15:3266-3274, 1997
12. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
13. O'Brien SM, Kantarjian H, Thomas DA, et al: Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19:2165-2170, 2001
14. Byrd JC, Murphy T, Howard RS, et al: Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19: 2153-2164, 2001
15. Byrd JC, Kitada S, Flinn IW, et al: The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: Evidence of caspase activation and apoptosis induction. Blood 99:1038-1043, 2002
16. Genini D, Budihardjo I, Plunkett W, et al: Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway. J Biol Chem 275:29-34, 2000
17. Cheson BD: Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 13:2431-2448, 1995
18. Byrd JC, Waselenko JK, Maneatis TJ, et al: Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: Association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 17:791-795, 1999
19. Alas S, Emmanouilides C, Bonavida B: Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 7:709-723, 2001
20. Di Gaetano N, Xiao Y, Erba E, et al: Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 114:800-809, 2001
21. Reff ME, Carner K, Chambers KS, et al: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445, 1994
22. Demidem A, Lam T, Alas S, et al: Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 12:177-186, 1997
23. Jones SE, Grozea PN, Miller TP, et al: Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma: A Southwest Oncology Group study. J Clin Oncol 3:1318-1324, 1985
24. Dana BW, Dahlberg S, Nathwani BN, et al: Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 11:644-651, 1993
25. Czuczman MS, Grillo-Lopez AJ, White CA, et al: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268-276, 1999
26. Czuczman MS: CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma. Semin Oncol 26:88-96, 1999 (suppl 14)
27. Czuczman MS, Grillo-Lopez AJ, McLaughlin P, et al: Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Ann Oncol 12:109-114, 2001
28. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244, 1999
29. Schemper M, Smith TL: A note on quantifying follow-up in studies of failure time. Control Clin Trials 17:343-346, 1996
30. Klasa RJ, Meyer RM, Shustik C, et al: Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen. J Clin Oncol 20:4649-4654, 2002
31. Solal-Celigny P, Brice P, Brousse N, et al: Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: A multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 14:514-519, 1996
32. Colombat P, Salles G, Brousse N, et al: Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation. Blood 97:101-106, 2001
33. Boldt DH, Von Hoff DD, Kuhn JG, et al: Effects on human peripheral lymphocytes of in vivo administration of 9-beta-D-arabinofuranosyl-2- fluoroadenine-5′-monophosphate (NSC 312887), a new purine antimetabolite. Cancer Res 44:4661-4666, 1984
34. Priebe T, Platsoucas CD, Nelson JA: Adenosine receptors and modulation of natural killer cell activity by purine nucleosides. Cancer Res 50:4328-4331, 1990
35. Priebe T, Ruiz L, Nelson JA: Role of natural killer cells in the modulation of primary antibody production by purine nucleosides and their analogs. Cell Immunol 130:513-519, 1990
36. Robertson LE, Denny AW, Huh YO, et al: Natural killer cell activity in chronic lymphocyte leukemia patients treated with fludarabine. Cancer Chemother Pharmacol 37:445-450, 1996
37. Janakiraman N, MP, White C, et al: Rituximab: Correlation between effector cells and clinical activity in NHL. Blood 92:337a, 1998 (abstr 1384)
38. Keating MJ, O'Brien S, Lerner S, et al: Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92:1165-1171, 1998
39. Zinzani PL, Lauria F, Rondelli D, et al: Fludarabine: An active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. Ann Oncol 4:575-578, 1993
40. Ross SR, McTavish D, Faulds D: Fludarabine: A review of its pharmacological properties and therapeutic potential in malignancy. Drugs 45:737-759, 1993
41. Pigaditou A, Rohatiner AZ, Whelan JS, et al: Fludarabine in low-grade lymphoma. Semin Oncol 20:24-27, 1993 (suppl 7)
42. Wijermans PW, Gerrits WB, Haak HL: Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol 50:292-296, 1993
43. Schulz H, Klein SK, Rehwald U, et al: Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 100:3115-3120, 2002
44. Byrd JC, Peterson BL, Morrison VA, et al: Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101:6-14, 2003
45. Lopez-Guillermo A, Cabanillas F, McLaughlin P, et al: The clinical significance of molecular response in indolent follicular lymphomas. Blood 91:2955-2960, 1998